| Pharmaceutical Information |
| Drug Name |
Ponesimod |
| Drug ID |
BADD_D02584 |
| Description |
Ponesimod is a selective sphingosine 1-phosphate receptor 1 modulator indicated in the treatment of relapsing forms of multiple sclerosis in adults.[A232079,L32709] Ponesimod was developed out of a need for a more selective modulator of sphingosine 1-phosphate receptor 1 than [fingolimod].[A232079] Fingolimod's activity at sphingosine 1-phosphate receptor 3 was suspected to be responsible for a portion of it's adverse effects, and so more selective modulators were developed.[A232079]
Ponesimod was granted FDA approval on 18 March 2021.[L32709] |
| Indications and Usage |
Ponesimod is indicated to treat adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.[L32709] |
| Marketing Status |
approved; investigational |
| ATC Code |
L04AA50 |
| DrugBank ID |
DB12016
|
| KEGG ID |
D11215
|
| MeSH ID |
C550169
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0Y4SI
|
| NDC Product Code |
50458-707; 50458-720 |
| UNII |
5G7AKV2MKP
|
| Synonyms |
ponesimod | 5-(3-chloro-4-(2,3-dihydroxy-propoxy)benzylidene)-2-propylimino-3-o-tolyl-thiazolidin-4-one | ponvory | ACT 128800 | ACT128800 | ACT-128800 |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
854107-55-4 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
| ADR Term |
ADReCS ID |
ADR Frequency (FAERS)
|
ADR Severity Grade (FAERS)
|
ADR Severity Grade (CTCAE)
|
| Therapy non-responder | 08.06.01.063 | 0.000820% | | - |
|
|
|
